Assisted reproductive outcomes of male cancer survivors
- 488 Downloads
The objective of our study was to evaluate the reproductive outcome of male cancer survivors treated with intracytoplasmic sperm injection (ICSI) using cryopreserved sperm and compare it with the same treatment in non-cancer males.
We retrospectively analyzed database derived from cancer and non-cancer patients undergoing sperm cryopreservation from August 2008 to August 2012 at a university-based center. We evaluated the reproductive outcome of those cancer and non-cancer patients that had frozen sperm and returned subsequently to the clinic for assisted reproduction.
We studied 272 males with cancer and 296 infertile males. The most prevalent types of cancer in our cohort were lymphoma (25.3 %), testicular cancer (19.2 %), leukemia (7.3 %), and other malignancies including sarcoma, gastrointestinal, and central nervous system malignancies (48.2 %). The use rate of cryopreserved sperm was 10.7 % for cancer patients and 30.7 % for non-cancer patients. The mean age of males with cancer who returned to the clinic for fertility treatment was 36.7 ± 6 years, and the diagnoses were testis cancer (43.4 %), lymphoma (36.9 %), leukemia (13 %), and other malignancies (6.7 %). Live birth rate of the cancer cohort was 62.1 %, which was higher than that of the normospermic non-cancer population (p < 0.0047).
The use rate of cryopreserved sperm from oncofertility preservation cases is at around 10 %. The live birth rate using assisted reproductive technologies among these patients is at least comparable to that of the non-cancer population.
Implications for Cancer Survivors
To our knowledge, this was the first comparative study of male cancer survivors treated with ICSI using cryopreserved sperm, which were compared to non-cancer males undergoing the same treatment. Male fertility preservation is a highly valued service that should be strongly encouraged prior to beginning cytotoxic cancer treatment. These results can help healthcare professionals in oncology to improve the quality of counseling on fertility preservation when managing young men with newly diagnosed cancer that require gonadotoxic treatment.
KeywordsMale cancer survivor Fertility Sperm cryopreservation Assisted reproductive technologies ICSI
The authors would like to thank Dr. Xun Zhang for his expertise in statistical analysis for all data in this study. This study was supported by a research grant from the Canadian Institutes for Health Research (CIHR) (SUR-103396) to Dr Peter Chan.
Conflict of interest
Ainhoa García, María Belén Herrero, Hananel Holzer, Togas Tulandi, and Peter Chan declare that they have no conflict of interest.
- 1.Fernbach A, Lockart B, Armus CL, Bashore LM, Levine J, Kroon L, et al. Evidence-based recommendations for fertility preservation options for inclusion in treatment protocols for pediatric and adolescent patients diagnosed with cancer. J Pediatr Oncol Nurs. 2014;31(4):211–22.CrossRefPubMedGoogle Scholar
- 11.WHO. World Health Organization WHO laboratory manual for examination and processing of human semen. 5th edition: Cambridge University Press 2010Google Scholar
- 13.Son WY, Chung JT, Henderson S, Reinblatt S, Buckett W, Chan PT, et al. Fertilization and embryo development with spermatozoa obtained from testicular sperm extraction into oocytes generated from human chorionic gonadotropin-primed in vitro maturation cycles. Fertil Steril. 2013;100(4):989–93.CrossRefPubMedGoogle Scholar
- 26.Grigorescu V, Zhang Y, Kissin DM, Sauber-Schatz E, Sunderam M, Kirby RS, et al. Maternal characteristics and pregnancy outcomes after assisted reproductive technology by infertility diagnosis: ovulatory dysfunction versus tubal obstruction. Fertil Steril. 2014;101(4):1019–25.CrossRefPubMedGoogle Scholar